附件99.1
Mallinckrodt達成協議出售Therakos® 以92500美元萬的價格實現業務對客户風險投資
資產剝離推進了Mallinckrodt的戰略重點，以優化資本結構並專注於核心專業領域
Mallinckrodt將利用淨收益將淨債務減少50%以上
CVC帶來資源和專業知識以進一步 開發Therakos並將其商業化
都柏林和盧森堡-2024年8月5日-全球專業製藥公司Mallinckrodt plc(“Mallinckrodt”或“公司”)和世界領先的投資公司之一CVC Capital Partners(“CVC”)今天宣佈，他們已達成最終協議。1根據該協議，CVC 資本夥伴基金IX 將以92500美元萬的收購價收購公司的Therakos業務，但須遵循慣例 調整。
Therakos是一種完全集成的體外光分離術(ECP)遞送系統，用於自體免疫調節治療。已獲準在美國、加拿大、歐洲、日本、澳大利亞和拉丁美洲使用， 它是醫療保健提供者和患者治療一系列免疫相關疾病的首選平臺。CVC在醫療保健方面擁有深厚的專業知識，並擁有涵蓋製藥、醫療技術和醫療保健服務的全球生命科學業務組合。該公司打算 在Therakos的持續研究、開發、適應症擴展和地理擴展方面進行額外投資。
根據協議條款，在Therakos 上工作的關鍵員工將與業務一起過渡，並繼續支持該產品及其利益相關者。
凱瑟琳·佩蒂和菲爾·羅賓遜(Phil Robinson)代表CVC醫療團隊表示：“我們看到了擴大Therakos的適應症、進入新地區並將這種創新療法帶給世界各地更多患者的重大機遇。我們期待着與才華橫溢的Therakos團隊密切合作，並將這種具有無與倫比的功效、安全性和耐受性的同類最佳ECP系統添加到我們的醫療保健業務組合中。“
Mallinckrodt首席執行官Siggi Olafsson、總裁和首席執行官Siggi Olafsson表示：“今天的聲明強調了我們致力於執行我們的戰略優先事項，併為我們的利益相關者創造價值。”這筆交易為Therakos業務提供了一個投資於其持續增長的理想合作伙伴，我們 期待着與CVC密切合作，為患者、醫療保健提供者、合作伙伴和員工的利益過渡Therakos。 我感謝Therakos團隊不斷致力於改善患者的生活。
Mallinckrodt打算使用交易淨收益將其淨債務減少 50%以上。交易預計將在2024年第四季度完成，這取決於監管部門的批准和 其他常規完成條件。
顧問
Lazard擔任Mallinckrodt的財務顧問，Wachtell，Lipton，Rosen&Katz擔任主要法律顧問，Arthur Cox擔任愛爾蘭法律顧問，A&O Searman 擔任其他國際地區的法律顧問。
1CVC還作出了不可撤銷的承諾，收購了經營Therakos業務的法國公司Therakos(France) SAS的股份。與CVC就Therakos(France)SAS股份達成的最終協議將在滿足當地信息要求後生效。
瑞銀將與富而德(Freshfield)(法律顧問)、普華永道(PWC)(金融)和坎迪西奇(Candesic)一起擔任CVC的財務顧問。
關於馬林克洛特
Mallinckrodt是一家全球性企業，由多家全資子公司組成，這些子公司開發、製造、營銷和分銷特種藥品和療法。該公司的專業 品牌可報告領域的重點領域包括神經科、風濕科、肝科、腎科、肺科、眼科和腫瘤科等專科領域的自身免疫性和罕見疾病；免疫療法和新生兒呼吸系統危重護理療法；止痛藥；以及胃腸 產品。其特種仿製藥可報告部門包括特種仿製藥和活性藥物成分。要了解有關Mallinckrodt的更多信息，請訪問www.mallinckrodt.com。
Mallinckrodt使用其網站作為發佈重要公司信息的渠道，例如新聞稿、投資者演示文稿和其他財務信息。它還利用其網站加快 公眾在發佈新聞稿或向美國證券交易委員會(“美國證券交易委員會”)提交披露相同信息的新聞稿或文件之前 獲取有關公司的關鍵時間信息。因此，投資者應 查看網站的投資者關係頁面，以獲取重要且時間緊迫的信息。網站訪問者還可以註冊 以收到自動電子郵件和其他通知，當網站的投資者關係頁面上有新信息時提醒他們。
CVC，傳播總監
nboard@cvc.com
Mallinckrodt、“M”品牌標誌和Mallinckrodt Pharmaceuticals 徽標是Mallinckrodt公司的商標。其他品牌是Mallinckrodt公司或其各自所有者的商標。© 2024。
Statements in this press release that are not strictly historical, including statements regarding future financial condition and operating results, expected product launches, legal, economic, business, competitive and/or regulatory factors affecting Mallinckrodt’s businesses, the ongoing strategic review, and any other statements regarding events or developments Mallinckrodt believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.
There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the parties’ ability to satisfy the conditions to the divestiture of the Therakos business, including required regulatory approvals, and the ability to complete the divestiture on the anticipated timeline or at all; the potential impact of the divestiture on our businesses and the risk that consummating the divestiture may be more difficult, time-consuming and costly than expected; changes in Mallinckrodt’s board of directors, business strategy and performance; Mallinckrodt’s evaluation of the assets across its portfolio, and its related pursuit of any divestiture opportunities including completion of the sale of Therakos; the exercise of contingent value rights by the Opioid Master Disbursement Trust II (the “Trust”); Mallinckrodt’s repurchases of debt securities; the liquidity, results of operations and businesses of Mallinckrodt and its subsidiaries; governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to Mallinckrodt or its officers; Mallinckrodt’s contractual and court-ordered compliance obligations that, if violated, could result in penalties; historical commercialization of opioids, including compliance with and restrictions under the global settlement to resolve all opioid-related claims; matters related to Acthar Gel, including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement; the ability to maintain relationships with Mallinckrodt’s suppliers, customers, employees and other third parties following the emergence from the 2023 bankruptcy proceedings, as well as perceptions of the Company's increased performance and credit risks associated with its constrained liquidity position and capital structure; the possibility that Mallinckrodt may be unable to achieve its business and strategic goals even now that the emergence from the 2023 bankruptcy proceedings was successfully consummated; the non-dischargeability of certain claims against Mallinckrodt as part of the bankruptcy process; developing, funding and executing Mallinckrodt's business plan; Mallinckrodt’s capital structure since its emergence from the 2023 bankruptcy proceedings; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt’s products due to legal changes or changes in insurers’ or other payers’ reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; any undesirable side effects caused by Mallinckrodt’s approved and investigational products, which could limit their commercial profile or result in other negative consequences; Mallinckrodt’s and its partners’ ability to successfully develop, commercialize or launch new products or expand commercial opportunities of existing products, including Acthar Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector and the INOmax Evolve platform; Mallinckrodt’s ability to successfully identify or discover additional products or product candidates; Mallinckrodt’s ability to navigate price fluctuations; competition; Mallinckrodt’s and its partners’ ability to protect intellectual property rights, including in relation to ongoing and future litigation; limited clinical trial data for Acthar Gel; the timing, expense and uncertainty associated with clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; business development activities or other strategic transactions; attraction and retention of key personnel; the effectiveness of information technology infrastructure, including risks of external attacks or failures; customer concentration; Mallinckrodt’s reliance on certain individual products that are material to its financial performance; Mallinckrodt’s ability to receive sufficient procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; reliance on third-party manufacturers and supply chain providers and related market disruptions; conducting business internationally; Mallinckrodt’s ability to achieve expected benefits from prior or future restructuring activities; Mallinckrodt’s significant levels of intangible assets and related impairment testing; natural disasters or other catastrophic events; Mallinckrodt’s substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness; restrictions contained in the agreements governing Mallinckrodt’s indebtedness and settlement obligation on Mallinckrodt’s operations, future financings and use of proceeds; actions taken by third parties, including the Company's creditors, the Trust and other stakeholders; Mallinckrodt’s variable rate indebtedness; Mallinckrodt's tax treatment by the Internal Revenue Service under Section 7874 and Section 382 of the Internal Revenue Code of 1986, as amended; future changes to applicable tax laws or the impact of disputes with governmental tax authorities; the impact of Irish laws; the impact on the holders of Mallinckrodt’s ordinary shares if Mallinckrodt’s were to cease to be a reporting company in the United States; the comparability of Mallinckrodt’s post-emergence financial results and the projections filed with the Bankruptcy Court; and the lack of comparability of Mallinckrodt’s historical financial statements and information contained in its financial statements after the adoption of fresh-start accounting following emergence from the 2023 bankruptcy proceedings.
The “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended December 29, 2023, Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2024, Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2024, to be filed with the SEC, and other filings with the SEC, which are available from the SEC’s website (www.sec.gov) and Mallinckrodt's (www.mallinckrodt.com), identify and describe in more detail the risks and uncertainties to which Mallinckrodt’s businesses are subject. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements.
Mallinckrodt Contacts
Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Patient Advocacy
Derek Naten
Vice President, Government Affairs
202-459-4143
derek.naten@mnk.com
Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
CVC Contacts
Nick Board
CVC, Director Communications
nboard@cvc.com
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024.